Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#CAR-TTherapyFailure

Home » #CAR-TTherapyFailure
Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

Posted by By Yang Xiaoshan 2024.03.17
Abstract: Refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) poses significant therapeutic challenges, particularly in cases where chimeric antigen receptor T-cell (CAR-T) therapy fails. This retrospective study aimed to evaluate the…
Read More
Recent Posts
  • ESMO Investigator Insights | Professor Qingyuan Zhang: Robust Clinical Evidence Demonstrates the Strength of Iza-bren, Ushering in a New Era of Breast Cancer Treatment
  • ESMO Investigator Insights | Professor Shusen Wang: Reshaping the Breast Cancer Treatment Landscape—How Iza-bren Is Ushering in a New Era of Bispecific ADC Therapy
  • ESMO Investigator Insights | Professor Yehui Shi: Confronting Challenges and Breaking New Ground—How the World’s First Bispecific ADC, Iza-bren, Is Ushering in a New Era of Bispecific ADC Therapy for Breast Cancer
  • 2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care
  • ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy
Recent Comments
    Archives
    • November 2026
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top